About the Award
The Controlled Release Society proudly presents the "New Drug Delivery-Enabled Product of the Year" award, a commendation that celebrates a groundbreaking product or technology introduced to patients within the last two (2) calendar years. This award is designated for a newly approved product that has significantly incorporated advanced drug delivery technology to enhance patient outcomes.
The scope of the award encompasses remarkable achievements across various domains of drug delivery, including advanced formulations, novel dose forms, cutting-edge devices, and pioneering delivery technologies. The honored product or technology exemplifies excellence in design, development, and application, setting a new benchmark for effectiveness, efficiency, and patient-centric solutions in the pharmaceutical industry.
The CRS extends this honor to the team of key innovators behind the recognized product—a group whose collective dedication and creativity have played a critical role in its conception and realization. A representative of the team will be presented with the team award, signifying the collaborative effort of the group. This team is acknowledged for their exceptional talent and leadership in navigating the complex journey from innovative idea to market success. The group's collaborative spirit and combined expertise have ensured that the product not only meets rigorous regulatory standards but also addresses an unmet medical need. Their synergy and shared vision exemplify the power of teamwork in transforming groundbreaking concepts into tangible healthcare solutions.
The "New Drug Delivery-Enabled Product of the Year" award underscores the importance of advanced drug delivery in achieving therapeutic breakthroughs, and the Controlled Release Society's commitment to supporting and highlighting advances that have a tangible impact on healthcare and patient care. It is a salute to the relentless pursuit of innovation and the collaborative spirit that drives the industry forward, ultimately leading to improved patient experiences and outcomes.
Criteria
- Drug in an enabled drug delivery system or drug device approved by any regulatory authority
- Drug delivery features must create a benefit for patient vs. current standard of care/molecule without such feature
- The nominee must have been part of the team that either invented or advanced the clinical use of drug delivery technology that enabled the product (e.g. not focusing on molecule discovery)
Selection Process
The following areas will be reviewed for eligibility by the Award Committee:
- Novelty of enabling technology as applied within indication and/or patient population (50%) [e.g. how innovative was the application of technology for the specific patient population targeted]
- Impact of the technology on differentiated patient outcomes (50%) [e.g. how clearly does the use of technology link to patient outcomes; it could enable a treatment not otherwise possible, or it could substantially improve patient experience/outcomes]
- CV will be required for any potential Annual Meeting speakers from finalist companies
Note: Nominations are not being accepted this year, the Award Committee will be curating nominations.
Award
- Award Plaque and recognition at the Annual Meeting
- Finalists to present a case study during Annual Meeting translational sessions
